Market Definition
Single-use systems (SUS) refers to biopharmaceutical manufacturing (bioprocessing) equipment designed to be used once (or for a single manufacturing campaign) and then discarded. Generally, SUS equipment is composed primarily of plastic components that have been sealed and sterilized using gamma irradiation
Market Insights
The Global Single Use System in Biopharma Manufacturing market is projected to grow at a CAGR of around 20.59% during the forecast period, 2022-27. The growth can be attributed to increase in production of vaccines, rising research & development activities, growing investments in the biopharma industry, etc. The global single use system in the biopharma market experienced significant growth in historical years, i.e., 2017-21, due to the rapid evolution of the technological & research landscape in the fields of biopharma manufacturing.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR (2022-2027) | 20.59% |
| Regions Covered | North America: The US, Canada |
| Europe: Germany, The UK, France, Rest of Europe | |
| Asia-Pacific: China, India, Japan, South Korea, Rest of Asia-Pacific | |
| South America: Brazil, Rest of South America | |
| Middle East & Africa: Saudi Arabia, South Africa, Rest of The Middle East & Africa | |
| Key Companies Profiled |
Sartorius AG (Sartorius Stedim Biotech), Entegris, Pall Corporation, Eppendorf, Corning Incorporated, ThermoFisher Scientific, PBS Biotech Inc., Lonza, Merck KGaA, Danaher Corporation, Kühner AG, Rentschler Biopharma SE, Getinge AB, Others |
| Unit Denominations | USD Million/Billion |
The emergence of COVID-19 impacted the biopharmaceutical industry both positively & negatively as most of the biopharma companies & research organizations initially struggled for the development of vaccines against the SARS-CoV-2 virus. As per the Pharmaceutical Research and Manufacturers of America, during January 2021, around 1,750 clinical trials were reported to be in the progress phase & out of which 420 belong to the US. These trials were operationalized for the development of vaccines & drugs in order to provide treatment for the COVID-19 virus. This, in return, has increased the demand for single use bioprocessing systems to be used in laboratories, biopharma companies, research institutes, etc., to cater to the growing demand for vaccines around the world. Consequently, there has been a constant rise in the production & utilization of single use bioprocessing systems.
